GSK Acquires Syndivia's Prostate Cancer ADC
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment.
Despite having its own ADC in development for prostate cancer, GSK is expanding its portfolio in this area.
The acquisition fuels the ongoing industry buzz for the promising anti-tumour modality.
The deal is valued at £268m.
GSK's move combines business intelligence and editorial excellence to reach engaged professionals.
Author's summary: GSK buys Syndivia's ADC for £268m.
More News
- First Duel Night Abyss Figure Is Based on Psyche
- Queer Issues are Human Issues - The McGill Daily
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Be ready for pea-sized hail with thunderstorms in Central West Florida Monday – gusts may reach 40 mph
- Bitcoin Price Might Never Fall Below $100,000 Again
- Zero Fatalities Pledges $10,000 in Discounted Lyft Rides for Halloween Weekend, Oct. 30 – Nov. 3
- The 2026 Legislative Season: Why Your Team Needs To Start Training Camp Now | JD Supra
- President Milei says he will seek consensus for new reform push
- Thunderstorms with damaging winds and penny-sized hail in Central West Florida Monday – wind gusts up to 60 mph
- SJHN Daily: Celebrini Named NHL First Star of the Week